Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 194

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 194
---
 Development Company, one of               
 the leading public companies in Israel, with numerous valuation studies of the company’s            
 major holdings.                                                                                     |
| ● | Given                                                                                               
 imaging. Various PPA and Impairment studies of Given Imaging SBUs (A global, leader in              
 patient-friendly solutions for visualizing, detecting, and monitoring GI disorders).                |
| ● | Kanit                                                                                               
 Hashalom. Numerous valuations of subsidiaries such as Tambour, Sonol, Supergas and GES.             |

Yours faithfully,

Moore Financial Consulting Ltd.

| Moore Financial Consulting |

| Teli.Valuation | November 2025Page 4 of 24 |

<div align='center'>Table of Contents</div>

| The                              
 Company                          |  5 |
| The                              
 Markets                          |  6 |
| Methodology                      | 11 |
| Valuation                        | 14 |
| Appendix                         
 – Benchmark Drugs and Treatments | 22 |

| Moore Financial Consulting |

| Teli.Valuation | November 2025Page 5 of 24 |

The Company

Telomir Pharmaceuticals, Inc. (“Telomir,”), is a pre-clinical-stage pharmaceutical development company.

Telomir-1 is a novel oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron and copper, Telomir-1 may help protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type 2 Diabetes, Cancer, and Alzheimer’s disease.

Telomir holds the marketing and sales rights for the geographic region that includes the USA, Canada and Mexico (North America) of the products it develops. Teli holds the marketing and sales rights for the rest of the world.

| Moore Financial Consulting |

| Teli.Valuation | November 2025Page 6 of 24 |

The Markets

Age Related Macular Degeneration (AMD) 1, 2

General

Age-related macular degeneration (AMD) is an eye condition that causes blurring of your central vision. It occurs when the macula, the part of the retina responsible for sharp, straight-ahead vision, becomes damaged due to aging. The macula is located in the retina,